The nomination period is underway for the Buzz of BIO contest at the 2020 CEO & Investor Conference! Winners receive complimentary conference registration, a company presentation in the corresponding track, and opportunities for promotion to industry leaders and investors.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. The conference will take place February 10-11 in New York, New York.
The Buzz of BIO contest provides an excellent opportunity for early-stage companies looking for their next financing round or late-stage private companies hoping to make the connections needed to take their product to the next phase.
Ten biotechs will be nominated in each of three categories: Public Therapeutic Biotech, Private Therapeutic Biotech, and our newest category, Diagnostics and Beyond.
- To qualify for the “Public Therapeutic Biotech” category, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and must be publicly traded
- To qualify for the “Private Therapeutic Biotech” category, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and must have raised at least $25MM by Nov. 2019, but must not yet be publicly traded.
- To qualify for the “Diagnostics and Beyond” category, companies must be primarily focused in medical diagnostics, drug delivery, drug development tools, or digital health technologies.
The first 10 qualifying completed entries in each category will become contest finalists eligible to receive the Grand Prize. Nominations close at 5:00 p.m. ET on November 21th, and voting opens December 3rd. Read the official contest rules here.
Early bird registration rates are available through December 31st.
Media registration is also available for qualified members of the press.
